Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ExternalLink');" target='_blank' href="http://www.nexavar.com/">www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG.  Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing.
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ), ... healthcare and to first responders on the federal, state ... the fiscal 2013 fourth quarter and year ended January ... market close and will conduct a conference call on ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... NEW YORK, Feb. 27, 2012 Delcath Systems, Inc., ... first patients in Germany have been treated with the ... Johann Wolfgang Goethe University Hospital, a premier European cancer treatment ... as part of the initial launch and training agreement ...
...  Osseon ® Therapeutics, Inc. announced today that ... Agreement with Aesculap AG to distribute its vertebral ... CE-Mark approved device – Osseoflex ® SB ... Asia.  Aesculap is a division of B. Braun ...
Cached Medicine Technology:Delcath Announces First CHEMOSAT Procedures in Germany 2Delcath Announces First CHEMOSAT Procedures in Germany 3Delcath Announces First CHEMOSAT Procedures in Germany 4Osseon® Announces International Distribution Agreement with Aesculap 2
(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... Show And Go Training, the culmination of Eric ... that is all about is getting results in the fastest ... http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting an investigative review. , ... phase system” designed to make you faster, stronger, fitter and ... out in the gym. The training manual and exercise video ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... of,Gujarat in India is now slowly coming to terms ... channels and papers are busy increasing the,death toll by ... and,the central government are now faced with the unenviable ... crammed with patients and doctors are,desperately needed in most ...
... were more likely to have an eating disorder when ... used to take less than their prescribed dose of ... insulin lead to early onset of diabetes related complications ... damage. Intensive treatment to diabetes could be the risk ...
... path breaking idea researchers at the just concluded Indian science ... with agricultural scientists to combat anemia with iron fortification of ... years of age are anemic in India. While iron supplementation ... in turn to fight anemia in people is fairly cheaper, ...
... blocked the related tissue experiences ischemia, a state of low ... as Ichemia / Reperfusion (IR) injury occurs during heart attacks. ... new drugs to save the damaged tissue and treat heart ... –1) level increases and acts like a common link between ...
... the New Year elbowing out the old year it is time ... work of 2000. And when we do that the first and ... of the genetic code. Almost all the top ten lists released ... remarkable feat in a prominent place and a majority of them ...
... the United States of America, a lawyer- Peter Angelos, who ... in Maryland, has announced that he is dragging Vodafone to ... to cell phone users who are said to have developed ... This case has raised eyebrows not only because of the ...
Cached Medicine News:Health News:Doctors needed urgently in Gujarat 2Health News:Doctors needed urgently in Gujarat 3Health News:Doctors needed urgently in Gujarat 4
... high gel strength, high electrophoretic mobility, ... agarose is the superior choice for ... remain easy to handle at concentrations ... shorter run times. Low background staining ...
... This new general-purpose agarose, like the ... quality tested (GQT) grade. This ensures that ... be manipulated without compromising quality. Certified molecular ... a very high molecular weight, resulting in ...
... of a set of reagents and instruments ... in hospital immunohematology labs and blood transfusion ... solutions in robotics, fluidics or the analysis ... monoclonal antibodies and the human antiglobulin reagents ...
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
Medicine Products: